Details of the Drug
General Information of Drug (ID: DMRBVFO)
Drug Name |
1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL445531; 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea; Oprea1_425301; Oprea1_433459; MolPort-001-590-368; ZINC5676460; STL504055; BDBM50267095; AKOS003326568; MCULE-4523135214; 1-(1-adamantyl)-3-(2-methoxyphenyl)urea; ST50933621; N-adamantanyl[(2-methoxyphenyl)amino]carboxamide
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 300.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||